|Generate QR code
Open Access
Subscription Access
Trajectories of long-term outcome of heart failure with concomitant chronic kidney disease: the significance of high-sensitivity C-reactive protein
https://doi.org/10.30629/0023-2149-2024-102-11-12-880-887
Abstract
Inflammation is intimately associated with atherosclerotic disease, including in patients with chronic heart failure (CHF), and high-sensitivity C-reactive protein (hsCRP) levels play a key role in determining severity and outcome.
Objective: to study the potential of serum hsCRP for predicting the outcome of ischemic heart failure in the presence of chronic kidney disease (CKD).
Material and methods. Clinical signs and 5-year outcomes of patients with CHF (n = 517), including those in combination with CKD (n = 207), were studied.
Results and conclusions. The phenotype of CHF in combination with CKD was characterized by female gender, older age, a higher prevalence of arterial hypertension, diabetes mellitus, previous myocardial infarction and coronary intervention, lower cardiorespiratory endurance, higher levels of hsCRP (p = 0.005), low-density lipoprotein cholesterol (p = 0.021), non-high-density lipoprotein cholesterol (p = 0.015). Patients with CHF with hsCRP > 3 mg/L have a higher 5-year risk of death from any cause, cardiovascular death, and achieving the composite endpoint (CCT). An increase in hsCRP for every 1 mg/l in CHF increases the risk of death from all causes (HR = 1.1; 95% CI 0.99–1.21), cardiovascular death (HR = 1.11; 95% CI 1.01–1.23). Death from any cause and cardiovascular death with CHF, incl. in the presence of CKD, hsCRP > 3.07 mg/l was predicted. Achieving CCT was predicted in patients with CHF with hsCRP > 2.69 mg/l, in patients with a combination of CHF and CKD — with hsCRP > 2.5 mg/l.
About the Authors
E. V. Khazova
Kazan State Medical University
Russian Federation
Russian Federation
Elena V. Khazova — Candidate of Medical Sciences, Associate Professor of the Department of propaedeutics of internal diseases named after professor S.S. Zimnitsky
Scopus Author ID: 57205153574
ResercherID O-2336-2016
RSCI AuthorID 639552
Kazan
O. V. Bulashova
Kazan State Medical University
Russian Federation
Russian Federation
Olga V. Boulashova — Doctor of Medical Sciences, Professor of the Department of propaedeutics of internal diseases named after professor S.S. Zimnitsky
Scopus Author ID: 6507198087
RSCI AuthorID 46110692
Kazan
References
1. van Deursen V.M, Urso R., Laroche C., Damman K., Dahlström U., Tavazzi L., Maggioni A.P., Voors A.A. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur. J. Heart Fail. 2014;16(1):103–11. DOI: 10.1002/ejhf.30
2. Efremova E.V., Shutov A.M. Comorbidity and prognosis in patients with chronic heart failure. Russian Heart Failure Journal. 2014;15(5):294–300. (In Russian).
3. Lazareva N.V., Oshchepkova E.V., Tereschenko S.N. Comorbidity in patients with heart failure (heart failure according the register). Russian cardiology bulletin. 2016;11(4):24–31. (In Russian).
4. Khazova E.V., Bulashova O.V. Do age and gender influence the phenotype of chronic heart failure? Practical medicine. 2022;20(7):85–95. (In Russian). DOI: 10.32000/2072-1757-2022-7-85-95.
5. Khazova E.V., Bulashova O.V., Amirov N.B. Is it necessary to determine highly sensitive C-reactive protein in patients with chronic heart failure: clinical and prognostic aspects. Bulletin of contemporary clinical medicine. 2022;15.(4):54–59. (In Russian). DOI: 10.20969/VSKM.2022.15(4).54-59
6. Jankowska E.A., Malyszko J., Ardehali H., Koc-Zorawska E., Banasiak W., von Haehling S., Macdougall I.C., Weiss G., McMurray J.J., Anker S.D., Gheorghiade M., Ponikowski P. Iron status in patients with chronic heart failure. Eur. Heart J. 2013;34(11):827–34. DOI: 10.1093/eurheartj/ehs377
7. Liu C., Li H. Correlation of the severity of chronic kidney disease with serum inflammation, osteoporosis and vitamin D deficiency. Exp. Ther. Med. 2019;17(1):368–372. DOI: 10.3892/etm.2018.6916
8. Nasybullina A.A., Bulashova O.V., Gazizyanova V.M., Malkova M. I., Mustafin E.E., Khusnutdinova G.R. Markers of inflammation in patients with heart failure in association with chronic kidney disease. Kazan Medical Journal. 2016;97(6):881–887 (In Russian). DOI: 10.17750/KMJ2016-881
9. Mościński M., Szyguła-Jurkiewicz B., Zakliczyński M., Rozentryt P., Partyka R., Zembala M., Poloński L. Five-year survival of patients with chronic systolic heart failure of ischemic and non-ischemic etiology: analysis of prognostic factors. Kardiochir. Torakochirurgia Pol. 2014;11(1):56–62. DOI: 10.5114/kitp.2014.41933
10. Kalogeropoulos A., Georgiopoulou V., Psaty B.M., Rodondi N., Smith A.L., Harrison D.G., Liu Y., Hoffmann U., Bauer D.C., Newman A.B., Kritchevsky S.B., Harris T.B., Butler J. Health ABC Study Investigators. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J. Am. Coll. Cardiol. 2010;55:2129–2137. DOI: 10.1016/j.jacc.2009.12.045
11. Pellicori P., Zhang J., Cuthbert J., Urbinati A., Shah P., Kazmi S., Clark A.L., Cleland J.G.F. High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovasc. Res. 2020;116(1):91–100. DOI: 10.1093/cvr/cvz198
12. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A., Gendlin G.E., Glezer M.G., Gautier S.V., Dovzhenko T.V., Kobalava Zh.D., Koziolova N.A., Koroteev A.V., Mareev Yu.V., Ovchinnikov A.G., Perepech N.B., Tarlovskaya E.I., Chesnikova A.I., Shevchenko A.O., Arutyunov G.P., Belenkov Yu.N., Galyavich A.S., Gilyarevsky S.R., Drapkina O.M., Duplyakov D.V., Lopatin Yu.M., Sitnikova M.Yu., Skibitsky V.V., Shlyakhto E.V. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–158. (In Russian). DOI: 10.18087/cardio.2475
13. Kukharchuk V.V., Yezhov M.V., Sergiyenko I.V. et al. Diagnostika i korrektsiya narusheniy lipidnogo obmena s tsel’yu profilaktiki i lecheniya ateroskleroza: Rossiyskiye rekomendatsii, VII peresmotr Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis: Russian recommendations, VII revision. Moskva, 2020:61. (In Russian).
14. Smirnov A.V., Shilov E.M., Dobronravov V.A., Kayukov I.G., Bobkova I.N., Shvetsov M.Yu., Tsygin A.N., Shutov A.M. National guidelines. chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. Nephrology (Saint-Petersburg). 2012;16(1):89–115. (In Russian). DOI: 10.24884/1561-6274-2012-16-1-89-115
15. Kramer F., Voss S., Roessig L., Igl B.W., Butler J., Lam C.S.P., Maggioni A.P., Shah S.J., Pieske B. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur. J. Heart Fail. 2020;22(9):1675–1683. DOI: 10.1002/ejhf.1787
16. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 1986;57(6):450–8. DOI: 10.1016/0002-9149(86)90771-x
17. Maqbool S., Shafiq S., Ali S., Rehman M.E.U., Malik J., Lee K.Y. Left Ventricular Hypertrophy (LVH) and Left Ventricular Geometric Patterns in Patients with Chronic Kidney Disease (CKD) Stage 2-5 With Preserved Ejection Fraction (EF): A Systematic Review to Explore CKD Stage-wise LVH Patterns. Curr. Probl. Cardiol. 2023;48(4):101590. DOI: 10.1016/j.cpcardiol.2023.101590
18. Murkamilov I.T., Sabirov I.S., Fomin V.V., Aitbaev K.A., Murkamilova Z.A. The relationship of hypertriglyceridemia and left ventricular remodeling types in patients with chronic kidney disease. Terapevticheskii arkhiv. 2019;91(6):93–99 (In Russian). DOI: 10.26442/00403660.2019.06.000047
19. Golino M., Moroni F., Abbate A. Connecting the Dots: Inflammatory Burden and Outcomes in Heart Failure. J. Am. Heart Assoc. 2023;12(19):e031786. DOI:10.1161/JAHA.123.031786
20. Menon V., Greene T., Wang X., Pereira A.A., Marcovina S.M., Beck G.J., Kusek J.W., Collins A.J., Levey A.S., Sarnak M.J. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68(2):766–72. DOI: 10.1111/j.1523-1755.2005.00455.x
21. Opotowsky A.R., Valente A.M., Alshawabkeh L., Cheng S., Bradley A., Rimm E.B., Landzberg M.J. Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank. Eur. Heart J. 2018;39(34):3253–3261. DOI: 10.1093/eurheartj/ehy362
22.
Review
For citations:
Khazova E.V., Bulashova O.V. Trajectories of long-term outcome of heart failure with concomitant chronic kidney disease: the significance of high-sensitivity C-reactive protein. Clinical Medicine (Russian Journal). 2024;102(11-12):880-887. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-11-12-880-887
Views:
136
Email this article 